Tu Yang-Yang, Huang Zhong-Ting, Zhang Zhi-Yong, Liu Dong-Liang, Qian Hai-Long
Department of Gastrointestinal Surgery, Ningbo Medical Center Li Hui Li Hospital, Ningbo, Zhejiang, 315000, China.
Open Life Sci. 2025 May 27;20(1):20251108. doi: 10.1515/biol-2025-1108. eCollection 2025.
This study aims to analyze and explore whether tumor biological three-dimensional printing (3DP) models can serve as reliable preclinical model research tools and assist in the personalized treatment of gastrointestinal stromal tumor (GIST) patients. Ten GIST cases admitted to our hospital from May 2024 to September 2024 were included in the personalized treatment group. Patient-derived GIST 3DP models were established, and treatment plans were selected based on the results of drug sensitivity tests. The progression-free survival (PFS) of the personalized treatment group was compared with that of GIST patients who had progressed after first-line treatment and were admitted to our hospital before the study. Treatment safety was also assessed. Immunofluorescence staining technology was used to observe tumor markers in the 3DP tumor models and their corresponding parent tumor tissues, revealing a high degree of consistency, which indicates that the 3DP tumor models highly retain the histological characteristics of the parent tumor tissues. The median PFS of patients in the personalized treatment group was 6.1 months, compared to 5.3 months in the previous treatment group, with a statistically significant difference (-value <0.05). The individualized drug sensitivity detection technology based on bio-3D printing technology, used for the personalized treatment of GIST patients who have progressed after first-line treatment, can benefit patients.
本研究旨在分析和探索肿瘤生物三维打印（3DP）模型是否可作为可靠的临床前模型研究工具，并协助胃肠间质瘤（GIST）患者的个性化治疗。将2024年5月至2024年9月我院收治的10例GIST病例纳入个性化治疗组。建立患者来源的GIST 3DP模型，并根据药敏试验结果选择治疗方案。将个性化治疗组的无进展生存期（PFS）与一线治疗后进展且在研究前入院的GIST患者进行比较。还评估了治疗安全性。采用免疫荧光染色技术观察3DP肿瘤模型及其相应的原发肿瘤组织中的肿瘤标志物，发现二者具有高度一致性，这表明三维打印肿瘤模型高度保留了原发肿瘤组织的组织学特征。个性化治疗组患者的中位PFS为6.1个月，而前一治疗组为5.3个月，差异有统计学意义（P值<0.05）。基于生物3D打印技术的个体化药敏检测技术用于一线治疗后进展的GIST患者的个性化治疗，可使患者受益。
